Medicine and Health Sciences | Executive Director at Masonic Medical Research Institute, United States
Dr. Maria Irene Kontaridis is a distinguished biomedical scientist and academic leader with an extensive background in cardiovascular research, molecular pharmacology, and translational medicine. She holds dual undergraduate degrees from the University of Florida and advanced degrees, including a Ph.D. in Biological and Biomedical Sciences from Yale University, where she also completed a Mini MBA. Her postdoctoral training at Yale and Harvard laid the foundation for a prolific career marked by influential faculty appointments at Harvard Medical School and Beth Israel Deaconess Medical Center. Currently serving as Executive Director and Gordon K. Moe Professor at the Masonic Medical Research Institute, she oversees strategic research initiatives, institutional growth, and scientific innovation. Dr. Kontaridis has led major national and international symposia, contributed to scientific and community development efforts, and is an advocate for women in science and academic leadership. Her interdisciplinary expertise, combined with her administrative acumen and philanthropic outreach, has positioned her as a transformative figure in biomedical research and academic medicine.
Professional ProfileĀ
š Education of Dr. Maria Kontaridis
Dr. Maria Kontaridis has an exceptional academic foundation marked by interdisciplinary excellence. She earned two undergraduate degrees in 1995 from the University of Floridaāa B.S. in Chemistry (Cum Laude) with a Minor in Business Administration, and a B.A. in Classical Studies (Summa Cum Laude). She pursued advanced scientific training at Yale University, completing a Master of Science (M.S.) in Pharmacology and Molecular Medicine in 1998, followed by an M.Phil. in 1999, and a Ph.D. in Biological and Biomedical Sciences in 2002 under the mentorship of Dr. Anton Bennett. Further enhancing her academic versatility, she obtained a Mini Master of Business Administration Certificate from Yale in 2000. In recognition of her scientific achievements and leadership, she was awarded an honorary Doctor of Science (D.Sc. h.c.) in 2025 by SUNY Polytechnic Institute, solidifying her stature as a leader in biomedical education and research.
š¼ Professional Experience of Dr. Maria Kontaridis
Dr. Maria Kontaridis has built a distinguished career in biomedical research, academic leadership, and institutional development. She began her professional journey with postdoctoral fellowships at Yale University and Harvard Medical School, focusing on pharmacology and hematology/oncology under the mentorship of esteemed scientists. Her academic appointments include progressive faculty roles at Harvard Medical School, where she served as Instructor, Assistant Professor, and later Associate Professor of Medicine, contributing to research, mentorship, and program development across multiple departments. She also held leadership roles at Beth Israel Deaconess Medical Center, including Director of Basic Cardiovascular Research and Faculty in Cardiovascular Medicine. Currently, she is the Gordon K. Moe Professor and Chair of Biomedical Research and Translational Medicine and the Executive Director at the Masonic Medical Research Institute (MMRI) in Utica, New York. At MMRI, she leads a team of over 60 researchers and staff, spearheads strategic initiatives, manages multimillion-dollar fundraising efforts, and drives national and international collaborationsāmaking her a dynamic force in advancing cardiovascular and translational medicine.
š¬ Research Interests of Dr. Maria Kontaridis
Dr. Maria Kontaridisās research is centered on unraveling the molecular mechanisms underlying cardiovascular diseases, congenital heart defects, and RASopathiesāa group of genetic syndromes caused by mutations in the RAS-MAPK pathway. Her work explores signal transduction pathways, particularly focusing on protein phosphatases, kinases, and their role in cardiac development, function, and remodeling. She has a strong interest in translational medicine, aiming to bridge the gap between basic science and clinical application by identifying novel therapeutic targets for heart failure, arrhythmias, and vascular abnormalities. Through her leadership at the Masonic Medical Research Institute, she has expanded her research scope to include regenerative medicine, stem cell biology, and precision medicine approaches for complex cardiovascular disorders. Her interdisciplinary focus integrates molecular biology, genetics, and pharmacology to develop innovative strategies for diagnosis and treatment, with a goal of improving patient outcomes in both pediatric and adult populations.
š
Awards and Honors of Dr. Maria Kontaridis
Dr. Maria Kontaridis has received numerous prestigious awards and honors that recognize her scientific excellence, leadership, and contributions to biomedical research. One of her most distinguished accolades is the Doctor of Science, honoris causa (D.Sc. h.c.), awarded by SUNY Polytechnic Institute in 2025, reflecting her impact on science and public service. Throughout her career, she has been appointed to prominent academic and leadership positions, such as the Gordon K. Moe Professorship and Executive Director at the Masonic Medical Research Institute, affirming her influence in the field of cardiovascular medicine. She has also been invited to chair and organize major international symposia and scientific meetings, including the Sarnoff Cardiovascular Research Foundation Annual Meeting and the International RASopathies Symposium. Additionally, her recognition extends beyond academia into civic and economic development, where she serves on advisory and leadership boards, underlining her role as a visionary leader committed to advancing both science and society.
š Conclusion
Dr. Maria Irene Kontaridis is highly suitable and deserving of the Best Researcher Award. Her career exemplifies excellence in academic leadership, global research collaboration, translational science, and mentorship. Her deep commitment to advancing cardiovascular medicine and biomedical innovation, combined with community involvement and advocacy for women in science, sets a benchmark for what this award represents.
š Publications Top Noted
-
Title: SHP2 happens, just sail with it: the role of the protein tyrosine phosphatase SHP2 in autoimmune and autoinflammatory diseases
Type: Review (Open Access)
Authors: Not listed in preview
Year: Not specified
Citations: 0
-
Title: Modulating the Secretome of Fat to Treat Heart Failure
Type: Review
Authors: Not listed in preview
Year: Not specified
Citations: 1
-
Title: Interorgan Crosstalk in Heart Failure and Cardiometabolic Diseases: A Compendium
Type: Review
Authors: Not listed in preview
Year: Not specified
Citations: 0
-
Title: RASopathies in Cardiac Disease
Type: Review (Open Access)
Authors: Not listed in preview
Year: Not specified
Citations: 0
-
Title: SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis
Type: Research Article
Journal: Nature Communications
Authors: Not fully listed; Dr. Maria Kontaridis is one of them
Year: 2024
Citations: 6